ProfileGDS5678 / 1432626_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 61% 62% 58% 61% 63% 67% 63% 61% 61% 63% 62% 54% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8083763
GSM967853U87-EV human glioblastoma xenograft - Control 23.6190161
GSM967854U87-EV human glioblastoma xenograft - Control 33.6761762
GSM967855U87-EV human glioblastoma xenograft - Control 43.4661458
GSM967856U87-EV human glioblastoma xenograft - Control 53.5925661
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8656763
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0850567
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7809963
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6588361
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6324161
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7537863
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6667262
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3612554
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.686362